SEC Form 4 · accession 0001209191-18-062116
Tempest Therapeutics, Inc. · TPST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mary Lynne Hedley
Director
Period of report
Dec 7, 2018
Accepted (ET)
Dec 11, 2018 · 7:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001544227
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $16.40 | Dec 7, 2018 | A | 18,600 | A | — | Aug 23, 2028 | Common Stock | 18,600 | 18,600 | D |
Explanation of responses
- F1Twenty-five percent (25%) of the shares subject to the option vested on February 24, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
- F2Received in connection with the merger of Millendo Therapeutics, Inc. ("Millendo") into the Issuer in exchange for a stock option to acquire 250,000 shares of Millendo common stock for $1.22 per share.